Bellicum Pharmaceuticals, Inc.

PHARMACY MARKET

Business Wire | September 28, 2023

Cytel Inc., provider of quantitative insights and health data analytics to leaders in the life sciences, has acquired the Berlin-based company co.faktor GmbH with its dedicated healthcare consultancy services co.value® (market access), co.medical® (medical communications), and co.patient® (patient relations) concentrations. As a result, Cytel’s services for biopharma commercializa...

Managed Healthcare Executive | March 02, 2020

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Business Insights

Ascletis Pharma Inc. | February 14, 2022

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Business Insights, PHARMACY MARKET

Businesswire | June 13, 2023

Veristat, a scientific-minded global clinical research organization (CRO), has acquired Scinopsis, a European medical writing consultancy with a 17-year track record of delivering regulatory and medical communication documents of the highest quality to the biopharmaceutical industry. The acquisition strengthens Veristat’s ability to meet growing client demand in one of its highest-valued service areas as the range of clinical trial content expands and the importance of regulatory doc...